Exogenous interleukin 2 regulates interleukin 6 and Nitric Oxide but not interferon γ and tumor necrosis factor a production in bronchoalveolar leukocytes from patients with small cell lung cancer

Archivum Immunologiae et Therapiae Experimentalis

Volumn 46, Issue 6, 1998, Pages 367-374

  Cembrzyńska Nowak, Monika ^a   Bieńkowska, Małgorzata ^a   Szklarz, Edward ^b  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b MILITARY HOSPITAL   (Poland)

Author keywords

Bronchoalveolar leukocytes; Interferon; Interleukin 2; Interleukin 6; Nitric oxide; Non small cell lung cancer; Small cell lung cancer; Tumor necrosis factor

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 6; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CALORIMETRY; CLINICAL ARTICLE; CYTOKINE PRODUCTION; FEMALE; HUMAN; IMMUNOREGULATION; IMMUNOSTIMULATION; INFLAMMATORY INFILTRATE; LEUKOCYTE COUNT; LUNG LAVAGE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE;

ADULT; BRONCHOALVEOLAR LAVAGE FLUID; CARCINOMA, SMALL CELL; CELLS, CULTURED; HUMANS; INTERFERON TYPE II; INTERLEUKIN-2; INTERLEUKIN-6; LEUKOCYTES; LUNG NEOPLASMS; MIDDLE AGED; NITRIC OXIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032418775     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. ARDIZZONI A., BONAVIA M., VIALE M., BALDINI E., MEREU C., VERNA A., FERRINI S., CINQUEGARNA A., MOLINARI S. and MARIANI G. L. (1994): Biologic and clinical effects of continuous infusion interleukin-2 in patients with non-small cell lung cancer. Cancer, 73, 1353-1360.
2. ARIAZ-DIAZ J., VARA E., TORRES-MELELERO J., GARCIA C., BAKI W., RAMIREZ-ARMENGOL J. A. and BALIBREA J. L. (1994): Nitrite/nitrate and cytokine levels in bronchoalveolar lavage fluid of lung cancer patients. Cancer, 74, 1546-1551.
3. CEMBRZYŃSKA-NOWAK M., INGLOT A. D., SZKLARZ E. and ALBIN M. (1990): Hyporesponsiveness of human alveolar leukocytes to interferon-alpha and interferon-gamma inducers. Immunology, 181, 84-96.
4. CEMBRZYŃSKA-NOWAK M., SZKLARZ E. and INGLOT A. D. (1997): Modulation of cytokine production by selenoorganic compound (AE-22) in hyperreactive or hyporeactive bronchoalveolar leukocytes fo asthmatics or lung cancer patients. J. Interferon Cytokine Res., 17, 609-617.
5. CHEN Y. M., YANG W. K., WHANGPENG J., TSAI W. Y., HUNG Y. M., YANG D. M., LIN W. C., PERNG R. P. and TING C. C. (1997): Restoration of the immunocompetence by IL-2 activation and TCR-CD3 engagement of the in vivo anergized tumor-specific CTL from lung cancer patients. J. Immunother., 20, 354-364.
6. CLAMON G., HERNDON J., PERRY M. C., OZER H., KREISMAN H., MAHLER T., ELLERTON J. and GREEN M. R. (1993): Interleukin-2 activity in patients with extensive small-cell lung cancer: a phase II trial of Cancer and Leukemia Group B. J. Natl. Cancer Inst., 85, 316-320.
7. DING A. H., NATHAN C. F. and STUEHR D. J. (1988): Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. J. Immunol., 141, 2407-2410.
8. ESPINOZA-DELGADO I., ORTALDO J. R., WINCKLER-PICKETT R., SUGAMURA K., VARESIO L. and LONGO D. L. (1990): Expression and role of p75 interleukin 2 receptor on human monocytes. J. Exp. Med., 171, 1821-1826.
9. FISCHER J. R., SCHINDEL M., BULZEBRUCK H., LAHM H., GALLATI H., KRAMMER P. H. and DRINGS P. (1997): Decrease of Interleukin-2 secretion is a new independent prognostic factor associated with poor survival in patients with small-cell lung cancer. Ann. Oncol., 8, 457-461.
10. FISCHER J. R., SCHINDEL M., STEIN N., LAHM H., GALLATI H., KRAMMER P. H. and DRINGS P. (1995): Selective suppression of cytokine secretion in patients with small-cell lung cancer. Ann. Oncol., 6, 921-926.
11. FLICK E. D. and GIFFORD G. E. (1984): Comparison of in vitro cell cytotoxic assays for tumor necrosis factor. J. Immunol. Methods., 68, 167-171.
12. GEMLO B. T., PALLADINO M. A., JAFFE H. S., ESPEVIK T. P. and RAYNER A. A. (1989): Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin-2 and lymphokine-activated killer cells. Cancer Res., 48, 5864-5867.
13. GENG Y., MAIER R. and LOTZ M. (1995): Tyrosine kinases are involved with the expression of inducible nitric oxide synthase in human articular chondrocytes. J. Cell. Physiol., 163, 545-554.
14. GREEN S. J., MELLOUK S., HOFFMAN S. L., MELTZER M. S. and NACY C. A. (1990): Cellular mechanisms of nonspecific immunity to intracellular infection: cytokine-induced synthesis of toxic nitrogen oxides from L-arginine by macrophages and hepatocytes. Immunol. Lett., 25, 15-19.
15. GREGORY S. H., SAGNIMENI A. J. and WING E. J. (1994): Arginine analogues suppress antigen-specific and -nonspecific T lymphocyte proliferation. Cell. Immunol., 153, 527-532.
16. HUANG M., WANG J. LEE P., SHARMA S., MAO T., MEISSNER H., UYEMURA K., MODLIN R., WOLLMAN J. and DUBINETT S. M. (1995): Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Res., 55, 3847-3853.
17. INGLOT A. D., MŁOCHOWSKI J., ZIELIŃSKA-JENCZYLIK J., PIASECKI E., LEDWOŃ T. K. and KLOCK K. (1996): Seleno-organic compounds as immunostimulants: an approach to the structure-activity relationship. Arch. Immunol. Ther. Exp., 44, 67-75.
18. JURETIC A., SPAGNOLI G. C., HORIG H., SHIPMAN R., KOCHER T., SAMIJA M., TURIC M., ELJUGA D., HARDER F. and HEBERER M. (1995): Tyrosine kinase-dependent and -independent events induced by interleukin-2 stimulation: interleukin-2-mediated NO production required for the induction of lymphokine-activated killer cell activity in rat splenocytes is tyrosine kinase independent. Immunology, 85, 325-330.
19. KAWABE T., ISOBE K. I., HASEGAWA Y., NAKASHIMA I. and SHIMOKATA K. (1992): Immunosuppressive activity induced by nitric oxide in culture supernatant of activated rat alveolar macrophages. Immunology, 76, 72-78.
20. 2 exposure. Lung, 174, 57-67.
21. LAGADEC P. F., SARAYA K. A. and BALKWILL F. R. (1991): Human small-cell lung-cancer cells are cytokine-resistant but NK/LAK-sensitive. Int. J. Cancer., 48, 311-317.
22. LEJEUNE P., LAGADEC P., ONIER N., PINARD D., OHSHIMA H. and JEANNIN J. F. (1994): Nitric oxide involvement in tumor-induced immunosuppression. J. Immunol., 152, 5077-5083.
23. LORENZ J., MULLER-QUERNMHEIM J., CASTILLO-HOFER C., DOBOSZYNSKA A. and FERLINZ R. (1990): Assessment of local cellular immunity in lung cancer by bronchoalveolar lavage. Klin. Wochenschr., 68, 728-734.
24. MCDONALD C. F. and ATKINS R. C. (1990): Defective cytostatic activity of pulmonary alveolar macrophages in primary lung cancer. Chest, 98, 881-885.
25. MELIS M., SPATAFORA M., MELODIA A., PACE E., GJOMARKAJ M., MERENDINO A. M. and BONSIGNORE G. (1996): ICAM-1 expression by lung cancer lines: effects of upregulation by cytokines on the interaction with LAK cells. Eur. Respir. J., 9, 1831-1838.
26. MIER J. W., VACHINO G., VAN DER MEER J. W., NUMEROF R. P., ADAMS S., CANNON J. G. BERNHEIM H. A., ATKINS M. B., PARKINSON D. R. and DINARELLO C. A. (1988): Induction of circulating tumor necrosis factor alpha (TNF-α) and the mechanism for the febrile response to interleukin-2 (1L-2) in cancer patients. J. Clin. Immunol., 6, 426-436.
27. MILES D., THOMSEN L., BALKWILL F., THAVASU P. and MONCADA S. (1994): Association between biosynthesis of nitric oxide and changes in immunological and vascular parameters in patients treated with interleukin-2. Eur. J. Clin. Invest., 24, 287-290.
28. MUSSO T., ESPINOZA-DELGADO I., GUSELLA G. L., LONGO D. L. and VARESSIO L. (1992): IL-2 induces IL-6 production in human monocytes. J. Immunol., 148, 795-800.
29. SAWADA T., FALK L. A., RAO P., MURPHY W. J. and PLUZNIK D. H. (1997): IL-6 induction of protein-DNA complex via a novel regulatory region of the inducible nitric oxide synthase gene promoter: role of octamer binding proteins. J. Immunol., 158, 5267-5276.
30. SERVE H., STEINHAUSER G., OBERBERG D., FLEGEL W. A., NORTHOFF H. and BERDEL W. E. (1991): Studies on the interaction between interleukin 6 and human malignant nonhematopoetic cell lines. Cancer Res., 51, 3862-3866.
31. STRIETER R. M., REMICK D. G., LYNCH J. P. 3rd., SPENGLER R. N. and KUNKEL S. L. (1989): Interleukin-2 induced tumor necrosis factor-alpha (TNF-α) gene expression in human alveolar macrophages and blood monocytes. Am. Rev. Respir. Dis., 139, 335-342.
32. STUEHR D. J. and NATHAN C. F. (1989): Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J. Exp. Med., 169, 1543-1555.
33. TAKIZAWA H., OHTOSHI T., OHTA K., YAMASHITA N., HIROHATA S., HIRAI K., HIRAMATSU K. and ITO K. (1993): Growth inhibitor of human lung cancer cell lines by interleukin-6 in vitro: a possible role in tumor growth via an autocrine mechanism. Cancer Res., 55, 4175-4181.
34. TESTA U., MONTESORO E., BULGARINI D., SAMOGGIA P., MASCIULLI R., HABETSWALLNER D., CARE A., MARIANI G., GIANELLA G. and BOCCOLI G. (1990): Interleukin 2 in cancer therapy. Ann. Inst. Super. Sanita., 26, 283-334.
35. THOMASSEN M. J., BUHROW L. T., CONNORS M. J., KANEKO F. T., ERZURUM S. C. and KAVURU M. S. (1997): Nitric oxide inhibits inflammatory cytokine production by human alveolar macrophages. Am. J. Respir. Cell. Mol. Biol., 17, 279-283.
36. TILG H., SHAPIRO L., VANNIER E., POUTSIAKA D. D., TREHU E., ATKINS M. B., DINARELLO C. A. and MIER J. W. (1994): Induction of circulating antagonists to IL-1 and TNF by IL-2 administration and their effects on IL-2 induced cytokine production in vitro. 3. Immunol., 152, 3189-3198.
37. VAN GAMERAN M. M., WILLEMSE P. H. B., MULDER N. H., LIMBURG P. C., GROEN H. J. M., VELLENGA E. and DE VRIES E. G. E. (1994): Effects of recombinant human interleukin 6 in cancer patients: a phase I-II study. Blood, 84, 1434-1441.
38. 2-terminal amino acid sequence of a T-cell derived lymphokine with growth factor activity for B-cell hybridomas. Proc. Natl. Acad. Sci. USA, 83, 9679-9683.
39. YAMAMOTO Y., KLEIN T. W. and FRIEDMAN H. (1996): Immunoregulatory role of nitric oxide in Legionella pneumophila-infected macrophages. Cell. Immunol., 171, 231-239.
40. YANAGAWA H., SONE S., MUNEKATA M., ATAGI S., NII A. and OGURA T. (1992): IL-6 in malignant pleural effusions and its augmentation by intrapleural instillation of IL-2. Clin. Exp. Immunol., 88, 207-212.
41. YIM C. Y., MCGREGOR J. R., KWON O. D., BASTIAN N. R., REES M., MORI M., HIBBS J. B. and SAMLOWSKI W. E. (1995): Nitric oxide synthesis contributes to IL-2-induced antitumor responses against intraperitoneal Meth A tumor. J. Immunol., 155, 4382-4390.
42. ZISSEL G., AULITZKY W. E., LORENZ J., HUBER C. and MULLER-QUERHEIM J. (1996): Induction of accessory cell function of human alveolar macrophages by inhalation of human natural interleukin-2. Cancer Immunol. Immunother., 42, 122-126.